Does Bevacizumab Cause Delayed Thromboembolism? Two Cases

Nisar Ahmad, Olugbenga Olowokure, Sajjad Haider, Nagla Abdel Karim

Abstract


Cancer patients are at increased risk of venous thromboembolism (VTE) and this risk may be further increased due to several other factors including chemotherapeutic drugs. Bevacizumab is a vascular endothelial growth factor (VEGF) inhibitor that has been reported to cause arterial and venous thrombosis during the treatment period. We present two cases of venous thrombosis occurring several weeks after stopping bevacizumab, raising the question of a delayed adverse drug effect due to the long half -life of the drug and immune complex formation.




J Med Cases. 2013;4(10):649-651
doi: https://doi.org/10.4021/jmc1464w

Keywords


Bevacizumab; Thromboembolism; Immune complexes

Full Text: HTML PDF
 

Browse  Journals  

 

Journal of Clinical Medicine Research

Journal of Endocrinology and Metabolism

Journal of Clinical Gynecology and Obstetrics

 

World Journal of Oncology

Gastroenterology Research

Journal of Hematology

 

Journal of Medical Cases

Journal of Current Surgery

Clinical Infection and Immunity

 

Cardiology Research

World Journal of Nephrology and Urology

Cellular and Molecular Medicine Research

 

Journal of Neurology Research

International Journal of Clinical Pediatrics

 

 
       
 

Journal of Medical Cases, monthly, ISSN 1923-4155 (print), 1923-4163 (online), published by Elmer Press Inc.                     
The content of this site is intended for health care professionals.
This is an open-access journal distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License, which permits unrestricted
non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Creative Commons Attribution license (Attribution-NonCommercial 4.0 International CC-BY-NC 4.0)


This journal follows the International Committee of Medical Journal Editors (ICMJE) recommendations for manuscripts submitted to biomedical journals,
the Committee on Publication Ethics (COPE) guidelines, and the Principles of Transparency and Best Practice in Scholarly Publishing.

website: www.journalmc.org   editorial contact: editor@journalmc.org
Address: 9225 Leslie Street, Suite 201, Richmond Hill, Ontario, L4B 3H6, Canada

© Elmer Press Inc. All Rights Reserved.